Press Releases

10/29/2021 Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
10/29/2021 Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
10/26/2021 Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
10/19/2021 GILEAD SCIENCES ANNOUNCES VEKLURY® DONATIONS TO HELP ADDRESS THE ONGOING COVID-19 CRISIS IN INDONESIA AND ARMENIA
10/18/2021 U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION OF GILEAD’S BIKTARVY® FOR TREATMENT OF HIV-1 IN PEDIATRIC POPULATIONS
9/22/2021 VEKLURY® (REMDESIVIR) SIGNIFICANTLY REDUCED RISK OF HOSPITALIZATION IN HIGH-RISK PATIENTS WITH COVID-19
3/16/2021 GILEAD AND MERCK ANNOUNCE AGREEMENT TO JOINTLY DEVELOP AND COMMERCIALIZE LONG-ACTING, INVESTIGATIONAL TREATMENT COMBINATIONS OF LENACAPAVIR AND ISLATRAVIR IN HIV
11/23/2020 Gilead Sciences Statement on The World Health Organization’s Updated Veklury (Remdesivir) COVID-19 Treatment Guidelines
10/23/2020 U.S. FOOD AND DRUG ADMINISTRATION APPROVES GILEAD’S ANTIVIRAL VEKLURY® (REMDESIVIR) FOR TREATMENT OF COVID-19
10/23/2020 An Open Letter from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences
10/9/2020 Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
10/9/2020 An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
9/17/2020 GILEAD’S MAGROLIMAB, AN INVESTIGATIONAL ANTI-CD47 MONOCLONAL ANTIBODY, RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF MYELODYSPLASTIC SYNDROME
9/17/2020 Gilead Sciences to Acquire Immunomedics
9/1/2020 GILEAD’S INVESTIGATIONAL ANTIVIRAL VEKLURY® (REMDESIVIR) RECEIVES U.S. FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION FOR THE TREATMENT OF PATIENTS WITH MODERATE COVID-19
8/11/2020 GILEAD SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF COVID-19
8/11/2020 China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
7/10/2020 GILEAD PRESENTS ADDITIONAL DATA ON INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR THE TREATMENT OF COVID-19
7/9/2020 GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19
7/3/2020 EUROPEAN COMMISSION GRANTS CONDITIONAL MARKETING AUTHORIZATION FOR GILEAD’S VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF COVID-19
6/30/2020 An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
6/23/2020 An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
6/18/2020 GILEAD SCIENCES STATEMENT ON PHASE 2/3 CLINICAL TRIAL OF REMDESIVIR IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19
6/2/2020 Gilead Sciences Statement on Remdesivir Clinical Data
6/1/2020 Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
5/23/2020 GILEAD SCIENCES STATEMENT ON NEJM PUBLICATION OF REMDESIVIR DATA FROM NIAID STUDY
5/13/2020 Voluntary Licensing Agreements for Remdesivir
5/8/2020 GILEAD ANNOUNCES APPROVAL OF VEKLURY® (remdesivir) IN JAPAN FOR PATIENTS HOSPITALIZED WITH SEVERE COVID-19
5/7/2020 GILEAD SCIENCES STATEMENT ON EXPANDING GLOBAL SUPPLY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR
5/2/2020 GILEAD’S INVESTIGATIONAL ANTIVIRAL REMDESIVIR RECEIVES U.S. FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION FOR THE TREATMENT OF COVID-19
4/30/2020 An Open Letter from our Chairman & CEO
4/29/2020 Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
4/29/2020 Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
4/24/2020 Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China
4/11/2020 An Open Letter from our Chairman & CEO
4/11/2020 DATA ON 53 PATIENTS TREATED WITH INVESTIGATIONAL ANTIVIRAL REMDESIVIR THROUGH THE COMPASSIONATE USE PROGRAM PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE
4/5/2020 An Update on COVID-19 from our Chairman & CEO
3/29/2020 An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
3/27/2020 Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation
2/27/2020 GILEAD SCIENCES INITIATES TWO PHASE 3 STUDIES OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR THE TREATMENT OF COVID-19
2/1/2020 Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)
8/15/2019 China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
12/9/2018 GILEAD SCIENCES NAMES DANIEL O’DAY CHAIRMAN AND CHIEF EXECUTIVE OFFICER
12/8/2018 Vemlidy Officially Launched in China (Currently Only Chinese Version is Available)
12/4/2018 China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of Hiv-1 Infection
12/4/2018 China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
11/19/2018 China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
10/20/2018 Genvoya® Officially Launched in China (Currently Only Chinese Version is Available)
9/14/2018 Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis
9/13/2018 GILEAD SCIENCES AND PRECISION BIOSCIENCES ANNOUNCE COLLABORATION TO DEVELOP THERAPIES AGAINST HEPATITIS B VIRUS USING ARCUS GENOME EDITING
8/31/2018 Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
8/6/2018 China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection
7/26/2018 Epclusa® Officially Launched in China (Currently Only Chinese Version is Available)
6/4/2018 Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B
5/29/2018 China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment For Chronic Hepatitis C Virus Infection
2/21/2018 Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
12/7/2017 Gilead Sciences and Kite Acquire Cell Design Labs
11/24/2017 Working for A World Free from Hepatitis C, Sovaldi® Officially Launched in China
10/20/2017 Treatment with Gilead’s Investigational Single Tablet Regimen Ledipasvir/Sofosbuvir Resulted in Cure Rates of 100 Percent in Chinese Chronic Hepatitis C Patients
9/25/2017 China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection
8/27/2017 Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
footer
© 2009-2019 Gilead. All rights reserved. Terms of Use  |  Privacy Statements
        Product images shown do not represent actual size.


沪ICP备18002020号   |   沪公网安备 31011502007450号  |   互联网药品信息服务资格证书：（沪） - 非经营性 -2018-0153